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Abstract
Autoimmune diseases such as myasthenia gravis (MG) result from an altered balance 
between the processes of activation and regulation of immune response. MG is the most 
common autoimmune disorder characterized by failure of transmission at the neu-
romuscular junction (NMJ). Autoantibodies in MG target the acetylcholine receptors 
(AChRs) as well as non-AChR components like muscle-specific tyrosine kinase (MuSK). 
Autoantibodies against AChRs are produced by B cells in the germinal centres (GCs), 
formed in the medulla of MG thymus and circulated to the post-synaptic side of the 
neuromuscular junction (NMJ) leading to complement-mediated destruction of the post-
synaptic folds of NMJ and internalization of AChRs. The incidence and prevalence of 
MG have increased particularly in elderly, but clinical presentations vary substantially 
and recognition depends on classic disease phenotype. This chapter focuses on clinical 
and immunological aspects of MG and its subgroups based on its characterization of the 
antigenic targets.
Keywords: autoimmune disorders, autoantibodies, myasthenia gravis, acetylcholine 
receptors, B-cell receptors, cell-based assays, seronegative myasthenia gravis
1. History of myasthenia gravis
Myasthenia gravis (MG) is an autoimmune syndrome caused by the failure of neuromuscu-
lar transmission, which results from the binding of autoantibodies to proteins involved in 
signalling at the neuromuscular junction. Neurobiology of myasthenia gravis states that it is 
an antibody-mediated autoimmune disorder where antibodies to the acetylcholine receptors 
(AChR) cause complement-mediated destruction of the post-synaptic folds of the neuromus-
cular junction (NMJ) and internalisation of AChRs. This results in reduced muscle-nerve syn-
aptic transmission and fatigable muscle weakness, one of the characteristic clinical features, 
in MG patients. It mainly affects the voluntary muscles including muscles of the neck, eyelids, 
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limb and diaphragm. Antibodies to AChRs and their effects on AChR number and function 
have been recognized since 45 years. However, their characterization and increasing recogni-
tion of antigenic targets added to understand different forms of MG.
Other subgroups of MG includes early-onset MG, late-onset MG, MuSK MG, seronegative 
MG (SNMG), neonatal MG, depends on the presentation and proteins involved in the dis-
ease. Some MG patients do not have detectable antibodies against AChRs and are termed 
as SNMG. In SNMG, antibodies are directed against the extracellular domain of Musk and 
inhibit agrin-induced AChR clustering in muscle myotubes [1]. Immunoglobulin G antibod-
ies against Musk have been described in [2] and IgM alters AChR in in vitro assays [1].
The incidence and prevalence has increased particularly in older individuals [3, 4]. The yearly 
incidence has also risen in all studies [5] due to significant increase among older males as well 
as females [6].
The role of the antibodies that cause myasthenia gravis was clearly established in the 1970s but 
characterization of antigenic targets evolved till now. Confirmation that antibodies to AChR 
alone could cause myasthenia gravis, came from immunisation against purified AChRs [7], and 
the fact that monoclonal antibodies to AChR can produce similar effects in laboratory animals 
[8]. However they also tested that plasma exchange, removes circulating antibodies, which 
leads to a substantial but transient improvement in muscle function lasting up to 2 months [9].
2. Diagnostic and clinical classification of MG
Autoantibodies against AChR were present in 85% sera of MG patient [10]. After few years, 
antibodies against MuSK were reported in 70% of patients with generalized seronegative 
MG [11]. Approximately 15% of patients with generalized MG do not have AChR antibod-
ies, previously defined as ‘seronegative’ MG and about 40% of them have antibodies against 
MuSK; about two-third of the remaining 60% has low-affinity antibodies against AChR 
undetectable by conventional assays [12, 13]. In MG, 90% of all cases are associated with 
MuSK and AChR antibodies and are convincingly pathogenic. Besides, some of the antibod-
ies can be associated with special clinical phenotypes. The clinical hallmark of MG is fatiga-
ble weakness, involving susceptible muscle groups in the body. It is the most characteristic 
feature of MG which becomes more evident on exertion and improves with rest. The course 
of MG is variable. Many patients experience intermittent worsening of symptoms triggered 
by infections, emotional stress, surgeries or medications, particularly during the first year 
of the disease.
3. Autoantibodies in MG
Early-onset myasthenia gravis is defined as presenting before age 40 years and is more com-
mon in women as per MG Foundation of America. Most are positive for AChR antibodies, 
and the thymus gland is enlarged. These patients have antibodies to other muscle antigens, 
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but might have other organ-specific autoantibodies [14–16]. Recently, it has been found that, 
tested serum from EOMG patients, females produced higher amounts of antibodies against 
clustered AChRs than males. On titration, no significant decrease in level of antibodies was 
observed. All these observations are summarized in Table 1 [17].
The targeted antibodies in most MG cases are against the Ach-gated cation channel α1 AChR 
[18]. Two isoforms of AChR, foetal and adult, differ in the composition of five subunits: 
the two α1, one δ and one β1 subunits, the foetal receptor contains one γ and replaced by 
one ε subunit in the adult receptor [17]. The main immunogenic region (MIR) is located to 
the extracellular top of the α1 subunit on the ACh binding site as shown in Figure 2. The 
antibodies against AChRs are mostly complement-fixing IgG1 or IgG3, which recognizes 
the native conformation easily. The conventional assay to detect AChR antibodies in the 
sera is radioimmunoprecipitation assay which is based on the mixture of foetal and adult 
125I- α –BuTx labelled AChR purified from a human muscle cell line. The sensitivity of the 
assay is about 80–85% in generalized MG. Alternatively, a non-radioactive cell-based assay 
(CBA) using cells co-transfected with AChR subunits and rapsyn that clusters AChR at NMJ, 
detected AChR antibodies in few patients, earlier regarded as ‘seronegative’ with conven-
tional RIPA [13].
Late-onset myasthenia gravis is defined as its first presentation in people older than 40 years. 
The thymus gland is not enlarged, but there is an HLA association with B7 and DR2 [17]. 
Thymoma-associated myasthenia gravis is not age specific, but can be presented at any age 
and the peak onset is during the 4th– 6th decades. There are no clear HLA associations. The 
patients usually have antibodies to other muscle antigens such as titin and ryanodine recep-
tor [18].
Generalised myasthenia gravis(MG) anti-AChR–seropositive (RIA)
Ocular MG Early-onset (EOMG) Late-onset (LOMG) Thymoma
Onset-age (years) 4–90 10–45 >45 >10
M:F ratio 3:2 1:3 3:2 1:1
% of all MG 20 20 50 10
HLA/other genes Not clear DR3/52a -- B8 
PTPN22 TNIP1
DR2/ 51 - B7 Not clear
Autoantibodies AChR MuSK AChR AChR Musk/AChR/ SN
AChR + or – +++ - + ++ ++
MuSK – – – –
Striated muscle/titin – – ++ (70%) ++ (>90%)
Thymic histology Hyperplasia + or – Hyperplasia (>80%) Atrophy Epithelial neoplasia 
(+adj. hyperplasia)
Age at onset, gender ratio and other factors in this chart describes clinical basis of Classification ‘OF’ MG with 
Clasification ‘IN’ MG, based on the estimated results on MG serum testing till 2013.
Table 1. Clinical classification of MG.
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Ocular myasthenia gravis is restricted to the eye muscles. The titres of antibodies to AChR are 
lowest in this subgroup, and undetectable in 40–60% of patients. However, electromyography 
and in vitro studies on muscle biopsy samples indicate that the disease is probably present 
sub-clinically in other muscles [19]. Ocular weakness, presenting as fluctuating ptosis and/or 
diplopia, is the most common initial presentation of MG, occurring in approximately 85% of 
patients [20].
MG with thymoma, about 10–15% of patients have thymoma, while 30% of thymomas are 
associated with MG. Thymoma is equally common in men and women. It can occur at any 
age, but the peak of onset is around 50 years. Thymoma associated with titin or especially 
with RyR antibodies may have more severe disease course similar to MuSK-MG, character-
ized by progressive oropharyngeal weakness. Thymoma is mostly associated with high titer 
of AChR antibodies. Its symptoms usually persist after thymectomy [21].
3.1. Neonatal MG
Neonatal MG occurs to the babies born to the women having MG regardless of its presen-
tation at the time of pregnancy. It is estimated to be 10% among individuals. It is caused 
by placental transfer of maternal IgG AChR antibodies. The mothers had very high titres of 
antibodies specific for the foetal isoform of the AChR, and low concentrations of antibodies 
directed towards the adult isoform of the AChR (Observations from EOMG patients).
3.2. Anti-Musk MG
Musk is a transmembrane endplate polypeptide involved in a signalling pathway that maintains 
the normal functional integrity of the NMJ as shown in Figure 1 [18, 22]. Musk antibodies are 
mainly IgG4 and are not complement activating, unlike the IgG1 and IgG3 anti-AChR antibod-
ies [26]. Anti-Musk antibodies adversely affect the maintenance of AChR clustering at the mus-
cle endplate, leading to reduced numbers of functional AChRs [20]. Apart from ELISA, a highly 
sensitive and specific cell-based assay using Musk-transfected HEK cells have been developed 
and its expression was found very high. Some of the sera of Musk-MG reacted with clustered 
AChRs as well, showing that low-affinity IgG and IgM antibodies to AChR may be present in 
a few Musk-MG patients [14]. IgG4 antibodies were previously known in autoimmune disease 
and thought to occur as a benign phenomenon in conjunction with resolution of allergic reac-
tions. However, they are recognised in other diseases, such as forms of pemphigus [27].
4. Other antibodies
Lrp4 is similarly essential as Musk in the development and function of the adult NMJ, where 
it performs both anterograde and retrograde signalling roles [24]. These roles highlighted it 
as a putative antigen of interest, and LRP4 antibodies have been reported in Japanese [28] and 
European patients. The antibodies were of the complement-activating IgG1 type [28, 29] and 
impeded agrin-induced clustering of AChRs.
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Agrin and collagen Q, antibodies to agrin have been identified in a small number of ‘triple 
negative’ MG sera (samples negative for AChR, Musk and LRP4 antibodies) at proportions 
from 15 to 50%. These antibodies sometimes at low titres were found only with AChR or 
MuSK antibodies [24]. ColQ tied with MuSK within the synapse, is thought to interact also 
with Musk. ColQ antibodies were reported in 3–4% of all MG patient sera tested and 1.2–5.5% 
of the AChR/MuSK/LRP4 negative samples [33].
5. Neuromuscular junction
The NMJ has three basic components, the presynaptic motor nerve terminal, site of acetyl-
choline synthesis, stored and released. Second is the synaptic space and third is the post-
synaptic muscle membrane, which contains the AChRs and the enzyme acetylcholinesterase. 
Neuromuscular transmission begins with the entry of nerve action potential into the nerve 
terminal and triggers the release of acetylcholine. Exocytosis of synaptic vesicles containing 
acetylcholine requires calcium, which enters the depolarised nerve terminal via voltage-gated 
Ca2+ channels. Acetylcholine diffuses across the synaptic cleft and interacts with the AChRs 
on the post-synaptic side of muscle, leading to depolarisation. The action of acetylcholine 
Figure 1. Structure of NMJ, the ion channels involved in neuromuscular transmission and disorders that affect it. The 
receptor muscle-specific kinase MuSK that now seems to be a major target in AChR seronegative myasthenia gravis is 
also shown along with other receptors [18].
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on the post-synaptic membrane is terminated by acetylcholinesterase. In MG, loss of func-
tional AChRs results in the decrease of threshold required for generation of muscle nerve 
fibre action potential during repetitive nerve depolarisations, resulting into neuromuscular 
transmission failure.
6. Structural characterization of AChRs
AChR remains the major antigenic target in MG followed by Musk, LRP4 and agrin. AChR 
is a pentameric membrane protein consisting of two α, one β, one δ and one ε subunit in the 
adult muscle, whereas, during development on child birth, the γ subunit takes the place of the 
ε. These subunits in respective isoforms are organized around a central cation channel. The 
two binding sites between α and ε or γ and α and δ need to be occupied to be in open state. 
The main immunogenic region (MIR) is on the extracellular component of each α subunit [13] 
(Figure 2).
7. Intra-thymic auto-immune mechanisms in MG
The thymus is an epithelial organ that can be divided into cortex, medulla and cortico-
medullary zone. The cortex contains immature lymphocytes alongside epithelial cells 
and macrophages. The medulla is less cellular containing more mature T lymphocytes, B 
lymphocytes, epithelial cells, dendritic cells and rare myoid cells. It plays a critical role in 
self-tolerance with a balance between the generation of T lymphocytes and deletion of auto-
reactive T cells, when required [25].
Figure 2. The acetylcholine receptor is a pentameric membrane protein; the membrane consists of five subunits: two α, 
one β, one δ and either gamma (foetal type) or epsilon (adult type). Acetylcholine and alpha-bungarotoxin bind to sites 
on the interfaces between the alpha subunit and adjacent subunits. Most of the antibodies in Myasthenia gravis bind to 
a main immunogenic region on the two α subunits [19].
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The thymus also has a critical role in AChR Ab+ EOMG patients, having lymphocytic infil-
trates in medullary region and germinal centres with distinct areas for B-cell proliferation, 
differentiation, somatic hypermutation and class switching [25] and thymoma cells do not 
[23]. Native AChR is also expressed by the myoid cells but are more abundant in hyperplas-
tic thymus [17]. Since a high proportion of patients with MG, demonstrate germinal centre 
hyperplasia of the thymus or cortical epithelial cell thymoma, the thymus gland was con-
sidered a solution to all forms of MG [31]. Whereas, thymectomy is associated with clini-
cal improvement, especially in young patients with thymus hyperplasia and recent disease 
onset [32].Normally, the thymus functions in early life to prevent autoimmune disorders by 
its inherent role in clonal deletion by negative selection of auto-reactive T cells and becomes 
regulatory T cells in early life [33]. Germinal centres normally arise in primary follicles within 
the secondary lymphoid organs, namely the spleen, lymph nodes and Peyer’s patches; these 
organs provide the necessary microenvironment for the germinal centre response. This justi-
fies the chances for having an autoimmune disorder was not affected by the age of onset of 
MG. Hence, indicate that acquired and non-genetic factors are involved in the establishment 
of the immune tolerance breakdown. The clinical impact of exposure to these acquired factors 
occurs later in life than the clinical impact of thymic involvement [34].
8. Molecular characterization of thymic B cells
Auto-reactive B cells and antibodies can be detected in a variety of neurological diseases. 
Their causative roles have been established in some disorders and are found to be involved in 
the pathogenesis of others. During the immune response against an antigen, B cells bearing 
antigen-specific receptors stimulate to proliferate and differentiate into antibody-secreting 
plasma cells within the germinal centres. This requires the presence of follicular dendritic 
cells (FDCs) and activated CD4 T-helper 1(Th-1) cells, CD40/CD40 ligand interaction, and a 
cocktail of cytokines to create the microenvironment necessary for a germinal centre reaction 
and a few B cells bearing an appropriate antigen receptors are stimulated to undergo clonal 
proliferation in the dark zone of the germinal centre and differentiation to centroblasts, cen-
trocytes, memory B cells and plasma cells. Antibody-secreting plasma cells migrate out of the 
follicle into the surrounding tissue [35].
Several markers on B cells during its proliferation, differentiation and development, charac-
terize them into subsets. CD 20, CD 19, CD 27 and CD 138 which are found on the surface of 
B cells and plasmablasts, are currently in research to develop B-cell–targeted immunotherapy 
to treat MG and other related autoimmune neurological disorders.
9. B-cell–directed immunotherapies
Pyridostigmine and corticosteroids plays a central role in the management of MG [36]. Use 
of azathioprine and other immunosuppressant drugs have been supported to treat MG. 
Intravenous Immunoglobulin and plasma exchange were also successful treatments for MG.
Myasthenia Gravis: Clinical and Immunological Aspects
http://dx.doi.org/10.5772/67684
137
Rituximab is a chimeric monoclonal antibody directed against the B-cell surface marker 
CD20. It reduces circulating B-cell counts, and on the basis of its potential for targeting auto-
reactive B-cell clones, have a therapeutic role in antibody-mediated autoimmune diseases 
[20]. It has been a useful treatment in IgG4-related diseases which eliminates a population 
of B or plasma cells responsible for the production of IgG4 antibodies, a targeted B-cell 
immunotherapy [30].
Ofatumumab is a fully monoclonal anti CD20 antibody which inhibits early B-cell develop-
ment. Ofatumumab induced enormous depletion of peripheral B lymphocytes in rheumatoid 
arthritis on the retreatment after rituximab [37]. It has been approved for treating chronic 
lymphocytic leukaemia. Its effect on development of B cells from MG patients’ thymus is 
currently under study [38–40] . There are several emerging therapies for MG, including tacro-
limus, rituximab and antigen-specific apheresis, whereas other treatments await clarification 
of efficacy and their role in MG. In addition, the complement inhibitory therapy has been 
shown to be effective in experimental MG [41] and might prove promising in myasthenic 
crisis and particularly in ocular MG, because of the low expression of complement regulators 
in extraocular muscle [41].
Recent findings that B cells have critical positive and negative roles in autoimmune disease 
[42] might lead to particularly effective therapeutic strategies that specifically target anti-AChR 
antibody-producing memory B cells.
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